07.27.18
Amgen
2Q Revenues: $6.1 billion (+4%)
2Q Earnings: $2.3 billion (+7%)
YTD Revenues: $11.6 billion (+3%)
YTD Earnings: $4.6 billion (+9%)
Comments: New and recently launched products including Repatha, KYPROLIS, Prolia and XGEVA, had double-digit growth, helping to offset declines for Enbrel, down 11% to $1.3 billion, Aranesp, Epogen and Neupogen, down 12%, 14% and 26% respectively. Repatha sales increased 78% to $148 million driven primarily by higher demand, offset partially by selling price. BLINCYTO sales increased 40% to $60 million driven by higher demand. KYPROLIS sales increased 25% to $263 million driven by demand, offset partially by selling price. Prolia sales increased 21% to $610 million driven by higher demand. XGEVA sales were up 14% to $452 million. Neulasta sales were up 1% to $1.1 billion driven by an increase in selling price and, to a lesser extent, favorable changes in inventory, offset partially by lower unit demand. Sensipar/Mimpara sales were down 2% to $420 million driven by unfavorable changes in inventory and lower unit demand.
2Q Revenues: $6.1 billion (+4%)
2Q Earnings: $2.3 billion (+7%)
YTD Revenues: $11.6 billion (+3%)
YTD Earnings: $4.6 billion (+9%)
Comments: New and recently launched products including Repatha, KYPROLIS, Prolia and XGEVA, had double-digit growth, helping to offset declines for Enbrel, down 11% to $1.3 billion, Aranesp, Epogen and Neupogen, down 12%, 14% and 26% respectively. Repatha sales increased 78% to $148 million driven primarily by higher demand, offset partially by selling price. BLINCYTO sales increased 40% to $60 million driven by higher demand. KYPROLIS sales increased 25% to $263 million driven by demand, offset partially by selling price. Prolia sales increased 21% to $610 million driven by higher demand. XGEVA sales were up 14% to $452 million. Neulasta sales were up 1% to $1.1 billion driven by an increase in selling price and, to a lesser extent, favorable changes in inventory, offset partially by lower unit demand. Sensipar/Mimpara sales were down 2% to $420 million driven by unfavorable changes in inventory and lower unit demand.